Spoken Alpha
TALPHERA, INC.
Talphera develops specialty pharmaceutical products for use in medically supervised hospital settings. The company's lead product, Niyad (nafamostat mesylate), is a regional anticoagulant in clinical trials for use during continuous renal replacement therapy in acute kidney injury patients.
TALPHERA, INC is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $56.6M market cap.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-10-04.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add TLPH, reply to your welcome email and we'll prioritize it.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TLPH.
$ curl https://api.spokenalpha.com/v1/companies/TLPHFAQ
Spoken Alpha indexes TLPH's earnings call transcripts at https://spokenalpha.com/companies/TLPH. Each call links to attributed speakers and parsed analyst Q&A. TALPHERA, INC.'s own investor relations page is at https://ir.talphera.com/.
TALPHERA, INC. (TLPH) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).